February 20, 2024
A Second Circuit panel on Tuesday declined to revive a class action accusing Allergan Ltd. of downplaying cancer risks linked to the company's breast implants, holding in a summary order that the investors failed to show any duty by Allergan to disclose certain information related to the alleged health concerns, or that the company made any false or misleading statements.
February 07, 2024
The Second Circuit on Wednesday wondered whether there was enough evidence to revive a class action lawsuit accusing Allergan Ltd. of downplaying cancer risks linked to the company's breast implants, with the judges questioning investor claims that public statements addressing the concerns left out necessary information.
July 27, 2023
Allergan Ltd. has urged the Second Circuit to uphold the dismissal of a class action alleging that the pharmaceutical company did not disclose a strong link between its breast implants and a rare form of cancer, or alternatively, to vacate the class certification.
December 12, 2022
A New York federal judge handed a win to Allergan PLC on Monday, ruling that a class of investors hasn't plausibly alleged that the company failed to disclose a "serious and known link" between the company's breast implants and a rare form of cancer.
September 09, 2021
A group of investors in pharmaceutical company Allergan PLC received class certification from a New York federal judge Wednesday for their allegations that the company failed to properly disclose a "serious and known link" between the company's breast implants and a rare form of cancer.
January 22, 2021
Investors in pharmaceutical company Allergan PLC urged a New York federal judge Thursday to grant class certification in their suit alleging the company failed to properly disclose a "serious and known link" between the company's breast implants and a rare form of cancer.
December 09, 2020
Faruqi & Faruqi will represent a proposed class of investors in the pharmaceutical company Allergan after Pomerantz lost its lead counsel status in the consolidated securities litigation, a Manhattan federal judge said Monday.
September 29, 2020
Allergan investors lost a bid to pursue a stock-drop suit as a class action against the pharmaceutical company, with a New York federal judge ruling Tuesday that the proposed lead plaintiff, which Allergan derided as a "serial litigant," isn't fit to represent the proposed class.
July 29, 2020
Pharmaceutical company Allergan on Tuesday told a New York federal judge not to certify a proposed class of its investors in a stock drop suit it faces, calling the lead plaintiff a "serial litigant" and contending that the trimmed suit didn't show the company's alleged misstatements moved the needle of the company's stock price.
February 03, 2020
Investors in pharmaceutical company Allergan are seeking certification for a shareholder class in their action, which alleges the company downplayed the connection between the company's breast implants and a form of cancer.